Everything below concerns lyophilized powder. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-03-02. Where a claim depends on a specific study, the study is described rather than over-claimed.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography, which separates the peptide from closely related impurities and from truncated or oxidized variants. Mass spectrometry supplies the molecular mass and confirms the expected sequence length, while amino acid analysis can be used to check composition. Because the molecule has no chromophore beyond the peptide backbone, ultraviolet detection is typically performed at a low wavelength, where baseline interference from solvents and buffers is a practical concern. Water content and counter-ion content are often reported alongside purity.
Practical handling focuses on limiting adsorption and contamination. The peptide dissolves readily in water, and dilute solutions tend to adhere to plastic and glass surfaces, so an inert carrier protein or a defined buffer can reduce losses in laboratory work. Workers also record the counter-ion form, since an acetate or trifluoroacetate salt changes the mass balance of the weighed powder. Documentation of lot number, purity value, and storage history supports reproducibility when results from different laboratories are compared.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
| Property | Value | Notes |
|---|---|---|
| Storage of dry powder | -20 °C or below | Common practice for long-term retention |
| Storage after reconstitution | 2-8 °C, short term | Solution stability is limited compared with dry powder |
| Typical analytical method | Reversed-phase HPLC | Usually paired with mass spectrometry for mass confirmation |
| Detection wavelength | About 214 nm | Peptide backbone absorbance; buffer background must be controlled |
| Counter-ion forms | Acetate or trifluoroacetate | Affects mass balance and reported concentration |
Several names appear in the literature for this peptide, including thymalfasin and the abbreviation T-alpha-1. Naming conventions differ among research articles, regulatory documents, and supplier catalogs, which complicates literature searches. Both synthetic and recombinant production routes yield a peptide with the same 28-residue sequence as the thymic isolate. Because the thymosin label also covers unrelated peptides, sources should be compared by sequence rather than by name alone.
The peptide occurs naturally in thymic tissue and has been detected in serum and other biological fluids. Reported concentrations are low, and reliable measurement generally requires immunoassay or mass spectrometry with an enrichment step. It is released from a larger precursor, prothymosin alpha, by proteolytic cleavage, although the enzymes involved are not fully characterized. Whether circulating levels reflect thymic output specifically remains an open question.
Thymosin alpha 1 is a 28-amino-acid peptide first isolated from thymosin fraction 5, a bovine thymic extract. Its sequence begins with an acetylated serine residue and carries a high proportion of acidic residues, so the molecule has a net negative charge near neutral pH. Despite the shared name, it is unrelated in sequence to the thymosin beta family. Synthetic material prepared by solid-phase peptide synthesis is identical in sequence to the natural peptide.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
=== In Anthropology === An anthropological lens challenges the idea that drug use is a universal problem, instead suggesting that perceptions of substance use and addiction depend on social, historical, political and cultural context. Drug policy and public responses vary globally, with disparities between the United Kingdom, Australia, and the United States. In the UK, drug use has become framed on crime prevention and coercion of drug users, demonstrating that definitions of harm are culturally and politically bound, questioning who health policies benefit. The USA has focused on the criminalisation of drug use, framing drug users as “morally reprehensible” and “deviant criminals”, shaping drug use as an issue of crime and social order. Australia’s 1985 adoption of harm minimisation strategies highlights that policy can shift alongside historical circumstances. The HIV/AIDS epidemic prompted a focus on safe injecting, rather than eradicating drug use. Maher and Dixon’s ethnographic research revealed that “attempts to suppress or control” drug use can shape how it is carried out, demonstrating that drug policy can shape experiences of harm. These cases corroborate Singer’s idea that drug use must be understood in its context, which challenges the narrative that drug-related harm is solely the users’ responsibility.
=== General ethical issues === If the creation of human DNA through artificial gene synthesis were to become technically feasible, several ethical and social issues have been identified by researchers. Scholars such as Adrian Villalba and Anna Smajdor have noted that synthetic DNA may challenge existing assumptions about the nature and significance of human genetic material. One area of concern involves the concept of genetic ownership. If a person’s DNA sequence can be artificially recreated in the laboratory, it becomes unclear who holds rights or control over the resulting material, and whether current legal and ethical frameworks are adequate to address such cases. There are also questions about identity. Human genomes have traditionally been viewed as closely linked to personal identity and biological heritage. However, the possibility of reconstructing or redesigning genomic sequences through synthetic DNA would significantly weaken this association. If genomes can be created, modified, or replicated independently of natural inheritance, the view that genetic makeup rigidly determines personal traits becomes increasingly difficult to sustain. In this context, synthetic DNA is proposed as effectively undermining genetic determinism and prompting a re-evaluation of assumptions about the role of genes in shaping individual identity. Privacy is another significant issue. The possibility of synthesizing sequences identical or similar to those of existing individuals raises concerns about genetic data protection and potential misuse.
Greater bulldog bats honk when on a collision course with each other. Bats also communicate by other means. Male little yellow-shouldered bats (Sturnira lilium) use a spicy odour secreted from their shoulder glands during the breeding season, retained and spread by specialised hairs. These hairs exist in other species, which are noticeable as collars around the necks in some Old World megabat males. Male greater sac-winged bats (Saccopteryx bilineata) have sacs in their wings in which they mix body secretions like saliva and urine to create a perfume that they sprinkle on roost sites, a behaviour known as "salting". The bats may sing while salting.
Sources: en.wikipedia.org
Different types of anxiety disorders will share some general symptoms while having their own distinctive symptoms. This explains why people with different types of anxiety disorders will respond differently to different classes of anti-anxiety medications.
=== Pharmacodynamics === Dimethocaine and structurally related local anesthetics such as cocaine and procaine inhibit the uptake of dopamine (DA) by blocking dopamine transporters (DAT). The dopamine transporter controls the dynamics of the neurotransmitter dopamine. This neurotransmitter controls many functions including movement, cognition and mood. Drugs such as cocaine and dimethocaine induce dopamine overflow by inhibiting dopamine transporters and thus creating a euphoric effect. In addition to inhibiting dopamine uptake, dimethocaine was also shown to inhibit the binding of CFT, a different dopamine uptake inhibitor. These inhibitory properties are responsible for the stimulatory effects of dimethocaine on the central nervous system. Both in vivo and in vitro measurements of dopamine transporter activity showed that dimethocaine is a potent and efficacious dopaminergic reuptake inhibitor (also called a dopamine indirect agonist). These effects were mainly observed in the nucleus accumbens, a region in the basal forebrain. Comparison of the pharmacological potencies of different local anesthetics revealed the following potency order: cocaine > dimethocaine > tetracaine > procaine > chloroprocaine Furthermore, the administration of dimethocaine has been shown to lead to antinociceptive responses at nontoxic doses in mice. These responses are suggested to be at least partially caused by the effects of dimethocaine on the central nervous system.
21 May The WHO informs about the international 2022 monkeypox outbreak in non-endemic countries – an unprecedented number of cases detected outside of Africa after the first of these cases was detected on 6 May. On 24 May, the WHO states that the outbreak can be contained. The main method used for the early containment is 'ring vaccination' – vaccinating close contacts of positive cases via existing vaccines. 23 May Researchers report that CRISPR-Cas9 gene editing has been used to boost vitamin D in tomatoes. A study shows why decarbonization must be accompanied by strategies to reduce the levels of short-lived climate pollutants with near-term effects for climate goals. 24 May Scientists report the first 3D-printed lab-grown wood. It is unclear if it could ever be used on a commercial scale (e.g. with sufficient production efficiency and quality). A CDC study based on electronic health records shows that "one in five COVID-19 survivors aged 18–64 years and one in four survivors aged ≥65 years experienced at least one incident condition that might be attributable to previous COVID-19" or long COVID. On 18 May, an analysis of private healthcare claims shows that of 78,252 patients diagnosed with 'long COVID', 75.8% had not been hospitalized for COVID-19. 25 May – The world's smallest remote-controlled walking robot, measuring just half a millimetre wide, is demonstrated. Potential applications include the clearing of blocked arteries.
In normal-phase TLC, the stationary phase is polar. Silica gel is very common in normal-phase TLC. More polar compounds in a sample mixture interact more strongly with the polar stationary phase. As a result, more-polar compounds move less (resulting in smaller RF) while less-polar compounds move higher up the plate (higher RF). A more-polar mobile phase dissolves polar compounds more. As such, all compounds on the TLC plate move higher up the plate in polar solvent mixtures. "Strong" solvents move compounds higher up the plate, whereas "weak" solvents move them less. If the stationary phase is non-polar, like C18-functionalized silica plates, it is called reverse-phase TLC. In this case, non-polar compounds move less and polar compounds move more. The solvent mixture will also be much more polar than in normal-phase TLC.
Sources: en.wikipedia.org
, in the half-plane. The circle shown in the figure indicates a surface on which the maximum shear stress is constant. From this stress field, the strain components and thus the displacements of all material points may be determined.
The neuroendocrine system is the mechanism by which the hypothalamus maintains homeostasis, regulating metabolism, reproduction, eating and drinking behaviour, energy utilization, osmolarity and blood pressure. The regulation of metabolism, is carried out by hypothalamic interconnections to other glands. Three endocrine glands of the hypothalamic–pituitary–gonadal axis (HPG axis) often work together and have important regulatory functions. Two other regulatory endocrine axes are the hypothalamic–pituitary–adrenal axis (HPA axis) and the hypothalamic–pituitary–thyroid axis (HPT axis). The liver also has many regulatory functions of the metabolism. An important function is the production and control of bile acids. Too much bile acid can be toxic to cells and its synthesis can be inhibited by activation of FXR a nuclear receptor.
The vintage logo sparked some controversy due in part to the siren's bare breasts, but the temporary switch garnered little attention from the media. Starbucks had drawn similar criticism when it reintroduced the vintage logo in 2006. The logo was altered when Starbucks entered the Saudi Arabian market in 2000 to remove the siren, leaving only her crown, as reported in a Pulitzer Prize-winning column by Colbert I. King in The Washington Post in 2002. The company announced three months later that it would be using the international logo in Saudi Arabia. In January 2011, Starbucks announced that it would make small changes to the company's logo, removing the Starbucks wordmark around the siren, enlarging the siren image, and making it green.
Sources: en.wikipedia.org
Cool storage below freezing is usual for long-term retention, with a desiccant and protection from light. Portions are often split before first use to avoid repeated handling.
Its sequence corresponds to the amino-terminal portion of prothymosin alpha, a larger protein present in many cell types. The isolated 28-residue peptide is a fragment of that protein rather than a separately encoded molecule, and laboratory material is produced by synthesis.
The single bridge between two cysteine residues holds the chain in a folded loop that influences its shape and its behavior in solution. Loss of the bridge through reduction or oxidation shifts chromatographic retention and is tracked during stability work.
It is a defined 28-residue sequence derived from a larger precursor, whereas many other thymic preparations are mixtures of several polypeptides. Its acetylated amino terminus and single disulfide bridge distinguish it chemically from unrelated thymic extracts.